You are here: Industry Insights > cancer drug

News List

EMA’s CHMP recommends Merck and Pfizer's cancer drug avelumab for approval pharmaceutical-technology
July 25, 2017
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued positive opinion recommending the approval of Merck and Pfizer's avelumab (BAVENCIO) as a monotherapy...
Ignyta's cancer drug entrectinib receives FDA orphan drug status pharmaceutical-technology
July 12, 2017
Biotechnology firm Ignyta has received orphan drug designation from the US Food and Drug Administration (FDA) for its investigational, orally available, CNS-active tyrosine kinase inhibitor, entrectinib, to treat NTRK fusion-positive solid tumours.
Statistical Approach to Clinical Trials may Accelerate Cancer Drug Development Process americanpharmaceuticalreview
April 17, 2017
A study published in JAMA Oncology by researchers from the Massachusetts Institute of Technology (MIT) and Mayo Clinic proposes a change to the framework for determining whether or not therapies are safe and effective.
Come-back for Lilly’s breast cancer drug pharmatimes
March 22, 2017
An experimental breast cancer combination being developed by Eli Lilly has hit its key goal of extending ...
Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval worldpharmanews
March 15, 2017
Further Milestone Payment Under Novartis Collaboration as Kisqali® (ribociclib) Receives FDA approval as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer with an aromatase inhibitor
Japan’s Takeda acquires US cancer drug manufacturer ARIAD for $5.2bn pharmaceutical-technology
February 20, 2017
Japan-based Takeda Pharmaceutical Company has completed the previously announced acquisition of American oncology company ARIAD Pharmaceuticals for $5.2bn.
New cancer drug could give hope to non-responsive patients pharmafile
February 16, 2017
A new dual action drug developed as part of a collaboration between biopharmaceutical oncology firm Almac Discovery and The Royal College of Surgeons in Ireland (RCSI) could be used to treat cancer patients in whom all other treatment avenues have failed.
Seattle Genetics gains rights to Immunomedics' experimental cancer drug sacituzumab govitecan firstwordpharma
February 13, 2017
Seattle Genetics agreed to license exclusive global rights to develop, manufacture and commercialise Immunomedics' experimental cancer drug sacituzumab govitecan under a deal potentially worth around $2 billion, the companies announced Friday.
Japan’s Takeda to acquire US cancer drug manufacturer ARIAD for $5.2bn pharmaceutical-technology
January 11, 2017
Japanese-based Takeda Pharmaceutical Company has signed an agreement to acquire American oncology company ARIAD Pharmaceuticals for approximately $5.2bn.

Previous page 1 2 3 4 5 6 Next page